Capstone Asset Management Co. cut its stake in shares of VWR Corporation (NASDAQ:VWR) by 10.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,600 shares of the medical research company’s stock after selling 1,070 shares during the period. Capstone Asset Management Co.’s holdings in VWR Corporation were worth $317,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Public Employees Retirement System of Ohio boosted its stake in shares of VWR Corporation by 3.4% in the first quarter. Public Employees Retirement System of Ohio now owns 31,762 shares of the medical research company’s stock valued at $896,000 after buying an additional 1,031 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in shares of VWR Corporation during the first quarter valued at about $100,000. Colony Group LLC boosted its stake in shares of VWR Corporation by 42.9% in the first quarter. Colony Group LLC now owns 135,356 shares of the medical research company’s stock valued at $3,817,000 after buying an additional 40,651 shares during the last quarter. Macquarie Group Ltd. boosted its stake in shares of VWR Corporation by 39.4% in the first quarter. Macquarie Group Ltd. now owns 1,933,570 shares of the medical research company’s stock valued at $54,527,000 after buying an additional 546,246 shares during the last quarter. Finally, Endurant Capital Management LP bought a new stake in shares of VWR Corporation during the first quarter valued at about $7,233,000.
Shares of VWR Corporation (NASDAQ:VWR) traded down 0.03% during trading on Friday, hitting $32.99. The company’s stock had a trading volume of 1,331,492 shares. The firm’s 50 day moving average price is $33.00 and its 200-day moving average price is $30.19. The company has a market cap of $4.35 billion, a PE ratio of 30.55 and a beta of 1.19. VWR Corporation has a 52 week low of $24.42 and a 52 week high of $37.25.
VWR Corporation (NASDAQ:VWR) last issued its earnings results on Monday, July 31st. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. VWR Corporation had a net margin of 3.12% and a return on equity of 15.54%. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the business posted $0.42 EPS. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. On average, analysts predict that VWR Corporation will post $1.86 earnings per share for the current year.
VWR has been the topic of several recent analyst reports. BidaskClub raised VWR Corporation from a “strong sell” rating to a “sell” rating in a report on Friday. Zacks Investment Research raised VWR Corporation from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Wednesday, August 2nd. William Blair lowered VWR Corporation from an “outperform” rating to a “market perform” rating in a report on Monday, May 15th. Finally, TheStreet raised VWR Corporation from a “c” rating to a “b-” rating in a report on Wednesday, April 19th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $30.50.
VWR Corporation Company Profile
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.